|
[Notice] Instructions for Changes to Approval Details (November 18, 2005)
2005.11.28
|
|---|
|
[Notice] Based on the Ministry of Food and Drug Safety Pharmaceutical Management Team-12079 (’05.11.18), the unified adjustment plan regarding the approval details (precautions for use) for fluoxetine hydrochloride single formulation (oral) and, based on the Ministry of Food and Drug Safety Narcotics Management Team-15069 (’05.11.18), the unified adjustment plan regarding approval details (indications, dosage and administration, precautions for use) for psychotropic anorectic agent phentermine hydrochloride formulation are as follows.
Affected products include: Depren Capsules (Fluoxetine Hydrochloride) Melcapt Tablets (Mercaptopurine) Festy Tablets (Phentermine Hydrochloride)
For inquiries related to this notice:
Responsible Department: Daehan New Pharm Development Division
Contact: 02-3415-7857 |


Home